Effect of Odanacatib on BMD and Fractures: Estimates from Bayesian Univariate and Bivariate Meta-analyses-Reference-Cited by-同舟云学术

Effect of Odanacatib on BMD and Fractures: Estimates from Bayesian Univariate and Bivariate Meta-analyses

Published:2014-09-01 Issue:9 Volume:99 Page:3070-3079
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Gajic-Veljanoski Olga¹,Tomlinson George²³,Srighanthan Jeevitha¹,Adachi Jonathan D.⁴,Josse Robert³⁵,Brown Jacques P.⁶,Cheung Angela M.¹²³

Affiliation:

1. Osteoporosis Program (O.G.-V., J.S., A.M.C.), University Health Network/Mt Sinai Hospital, Toronto, ON M5G 2C4, Canada

2. Institute of Health Policy, Management and Evaluation (G.T., A.M.C.), Toronto, ON M5T 3M6, Canada

3. Department of Medicine (G.T., R.J., A.M.C.), University of Toronto, Toronto, ON M5T 3M6, Canada

4. St Joseph's Healthcare and McMaster University (J.D.A.), Hamilton, ON L8N 1Y2, Canada

5. St Michael's Hospital (R.J.), Toronto, ON M5C 2T2, Canada

6. Centre Hospitalier Universitaire de Québec Research Centre and Laval University (J.P.B.), Quebec, QC G1V 4G2, Canada

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/99/9/3070/9048627/jcem3070.pdf

Reference62 articles.

1. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis;Costa;Nat Rev Rheumatol,2011

2. Papapoulos S , BoneH, DempsterD, et al. Phase 3 fracture trial of odanacatib for osteoporosis–baseline characteristics and study design. J Bone Miner Res. 2012;27(suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=8dbc5fc5-2225-4249-8504-d02bb8663d10. Accessed December 2, 2013.

3. Merck Co, Inc. A study of MK-0822 in postmenopausal women with osteoporosis to assess fracture risk (MK-0822-018). http://clinicaltrials.gov/ct2/show/NCT00529373?term=NCT00529373&rank=1. Accessed November 27, 2013

4. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density;Bone;J Bone Miner Res,2010

5. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture and estimated bone strength [published online February 12, 2014];Cheung;J Bone Miner Res

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of odanacatib in the treatment of postmenopausal women with osteoporosis: a meta-analysis;Journal of Orthopaedic Surgery and Research;2024-08-29

2. Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis;Archives of Osteoporosis;2023-05-11

3. Efficacy of Intraperitoneal Administration of PEGylated NELL-1 for Bone Formation;BioResearch Open Access;2016-06-01

4. Odanacatib for the treatment of osteoporosis;Expert Opinion on Pharmacotherapy;2015-07-06

5. Diabetes and Congenital Heart Defects;American Journal of Preventive Medicine;2015-02